Laboratory findings of patients with COVID-19 with or without new-onset CVD
| Total (N=219) | COVID-19 with CVD (n=11) | COVID-19 without CVD (n=208) | P value* | |
| White blood cell count, ×109/L | 5.0 (0.1–20.4) | 7.7 (3.9–14.8) | 4.9 (0.1–20.4) | 0.002 |
| Neutrophil, ×109/L | 3.1 (0.0–18.7) | 6.4 (0.0–13.8) | 3.0 (0.0–18.7) | 0.003 |
| Lymphocyte count, ×109/L | 1.1 (0.1–2.6) | 0.6 (0.3–1.2) | 1.1 (0.1–2.6) | <0.001 |
| Platelet count, ×109/L | 206.0 (18.0–583.0) | 142.0 (90.0–564.0) | 211.0 (18.0–583.0) | 0.035 |
| C reactive protein (mg/L) | 12.5 (0.1–212.0) | 51.1 (1.3–127.9) | 12.1 (0.1–212.0) | 0.025 |
| D-dimer (mg/L) | 0.5 (0.1–20.0) | 6.9 (0.3–20.0) | 0.5 (0.1–20.0) | <0.001 |
| Alanine aminotransferase (U/L) | 26.0 (5.0–1933.0) | 24.0 (13.0–144.0) | 26.5 (5.0–1933.0) | 0.671 |
| Aspartate aminotransferase (U/L) | 26.0 (8.0–8191.0) | 32.0 (19.0–271.0) | 26.0 (8.0–8191·0) | 0.119 |
| Blood urea nitrogen (mmol/L) | 4.1 (1.5–48.1) | 7.4 (4.0–43.2) | 4.1 (1.5–48.1) | <0.001 |
| Creatinine (μmol/L) | 68.3 (35.9–9435.0) | 75.5 (42.7–261.3) | 68.2 (35.9–9435.0) | 0.02 |
P values indicate differences between patients with COVID-19 with and without new-onset CVD. P<0.05 was considered statistically significant.
*Wilcox non-parameter test.
CVD, cerebrovascular disease.